News & Investors

Investor Relations

Corporate Profile

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit.

Stock Price

May 26, 2022 7:31 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News
May 26, 2022
Forma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) Day
May 06, 2022
Forma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 29, 2022
Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022
May 26, 2022
8:00 AM - 10:00 AM EDT
Forma Therapeutics R&D Day
Learn more
May 6, 2022
8:00 AM EDT
Forma Therapeutics First Quarter 2022 Financial Results and Business Update
Learn more
Mar 16, 2022
8:40 AM EDT
Oppenheimer Healthcare Conference
Learn more